McAdam LLC’s Sarepta Therapeutics SRPT Stock Holding History

McAdam LLC’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-80	Closed	-$6K	–	792
2018 Q1	$6K	Buy	+80	New	+$5.33K	﹤0.01%	396

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

McAdam LLC's SRPT Position: Q2 2018 in Review

McAdam LLC sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 80 shares — an estimated $6K sold.

McAdam LLC first reported a position in SRPT in Q1 2018 and held it in 1 quarter. The position peaked at $6K in Q1 2018. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

McAdam LLC reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
McAdam LLC sold 80 Sarepta Therapeutics shares in Q2 2018, an estimated $6K.
McAdam LLC first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 1 quarter.
McAdam LLC's Sarepta Therapeutics position peaked at $6K in Q1 2018.
317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on McAdam LLC's 13F filing for Q2 2018, filed 22 Aug 2018.